Research analysts covering Abivax.
Recent press releases and 8-K filings for ABVX.
Abivax Presents Third Quarter 2025 Financial Results
ABVX
Earnings
Guidance Update
- Abivax reported a net loss of EUR 254.1 million for the nine months ended September 30, 2025, an increase from EUR 136.9 million for the same period in 2024. This was primarily driven by an increased operating loss of EUR 174.4 million, largely due to a EUR 25.4 million increase in Research and Development expenses to EUR 133.4 million.
- As of September 30, 2025, Abivax held cash and cash equivalents of EUR 589.7 million, a substantial increase from EUR 144.2 million at December 31, 2024.
- This significant increase in cash was primarily due to net proceeds of approximately EUR 597.2 million from a public offering completed in July 2025.
- The company anticipates that its current cash position will provide a cash runway into the fourth quarter of 2027.
Dec 15, 2025, 9:13 PM
ABIVAX Presents Obefazimod Phase 3 Induction Data at UEG Week
ABVX
- ABIVAX presented late-breaking abstract results for its first-in-class molecule, obefazimod, at UEG Week 2025, demonstrating efficacy in induction across various patient populations, including naive and refractory patients.
- The Phase 3 program for obefazimod included a severe and refractory patient population, notably those who had failed JAK inhibitors, with positive results.
- The safety profile was generally good, with headaches identified as a common but transient adverse event, believed to be related to the parent drug and resolving within 10 days.
- Future data releases for obefazimod include top-line quality of life data in November and biomarker data, with maintenance data also anticipated.
- Physicians expressed enthusiasm for obefazimod's potential as an oral treatment for ulcerative colitis, with market research suggesting it could potentially expand the market to up to 100,000 patients in the U.S. currently on conventional therapy.
Oct 6, 2025, 1:00 PM
Abivax discusses positive obefazimod data from UEG conference
ABVX
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Abivax presented positive results for its first-in-class molecule, obefazimod, at the UEG conference, demonstrating efficacy in induction across both naive and highly refractory patient populations.
- The 50mg dose of obefazimod showed significant endoscopic improvement and better deltas in refractory patients, providing hope for those who have failed previous therapies.
- In the Phase II-B study, 66% of patients in the open-label extension achieved remission at one year, with 40% of initial non-responders at eight weeks converting to remission by one year.
- Abivax anticipates releasing top-line Phase III quality of life data in November and will provide further updates on biomarker and clinical combination data.
- Market research indicates a potential 33% market share in the refractory population and 15% in the naive population, with the drug potentially expanding the U.S. market by up to 100,000 patients.
Oct 6, 2025, 1:00 PM
Abivax Discusses Positive Oripazimod Phase III Data at UEG Conference
ABVX
Product Launch
New Projects/Investments
- Abivax presented positive oripazimod Phase III data at the UEG conference, demonstrating its efficacy in inducing remission across both naive and highly refractory ulcerative colitis patient populations.
- The primary outcome metric showed a 16% delta for the 50mg dose and 13% for the 25mg dose between effective arms and placebo, with significant clinical remission and endoscopic improvement, particularly in refractory patients.
- The company plans to release top-line quality of life data in November, along with biomarker and clinical combination data in the coming months.
- Market research indicates a potential 32% market share in the refractory population and 15% in the naive population, with a potential market expansion of up to 100,000 patients in the US.
Oct 6, 2025, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more